• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
BD1
Click for more information
1.63% $3.11

BARD1 LIFE SCIENCES LIMITED - Announcements

Currently unlisted. watchlist Created with Sketch. Add to my watchlist

BARD1 Life Sciences Ltd is an Australia-based life sciences company. The Company is... BARD1 Life Sciences Ltd is an Australia-based life sciences company. The Company is engaged in developing diagnostics and therapeutics for unmet needs in cancer. Its proprietary BARD1 Technology is based on BARD1, a potent tumour suppressor in healthy individuals and important tumour biomarker in cancer. Its lead product the BARD1 Lung Cancer Test is a non-invasive blood test in development for early detection of lung cancer. It is also engaged in researching a pipeline of potential diagnostic and therapeutic products for multiple cancers. The Company’s pipeline also includes BARD1 Ovarian Cancer Test and BARD1 Ribonucleic Acid (RNA) Test.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
Filters [Clear]
  • Price Sensitive: Yes
BD1 Half Yearly Report and AccountsPRICE SENSITIVE28/02/19
BD1 Cancer Vaccine Study ResultsPRICE SENSITIVE15/02/19
BD1 Quarterly Business Update and Appendix 4CPRICE SENSITIVE25/01/19
BD1 Closure of Entitlement Offer and ShortfallPRICE SENSITIVE12/12/18
BD1 Rights Offer DocumentPRICE SENSITIVE19/11/18
BD1 Capital Raising Indicative TimetablePRICE SENSITIVE12/11/18
BD1 Non-Renounceable IssuePRICE SENSITIVE08/11/18
BD1 Trading HaltPRICE SENSITIVE07/11/18
BD1 Pause In TradingPRICE SENSITIVE07/11/18
BD1 Quarterly Activities Report and CashflowPRICE SENSITIVE31/10/18
BD1 Grant of Additional Chinese Patent Core BARD1 Patent FamilyPRICE SENSITIVE24/10/18
BD1 Development of world first BARD1 Breast Cancer TestPRICE SENSITIVE23/10/18
BD1 Bard1 Ovarian Test ResultsPRICE SENSITIVE06/09/18
BD1 Appendix 4EPRICE SENSITIVE31/08/18
BD1 Quarterly Activities Report and Appendix 4CPRICE SENSITIVE01/08/18
BD1 US Patent Issued Protecting BARD1 Ovarian TestPRICE SENSITIVE12/07/18 download Created with Sketch. 141.15KB
BD1 Improved Performance of BARD1 Ovarian TestPRICE SENSITIVE19/06/18 download Created with Sketch. 136.84KB
BD1 Reinstatement to Official QuotationPRICE SENSITIVE18/05/18
BD1 Response to ASX Price QueryPRICE SENSITIVE18/05/18
BD1 Contract Development Agreement SignedPRICE SENSITIVE18/05/18
BD1 Voluntary SuspensionPRICE SENSITIVE14/05/18
BD1 Trading HaltPRICE SENSITIVE10/05/18
BD1 Quarterly Business Update and Appendix 4CPRICE SENSITIVE30/04/18
BD1 Capital RaisingPRICE SENSITIVE22/03/18
BD1 Israeli Patent Issued in Bard1 Core Patent FamilyPRICE SENSITIVE21/03/18
BD1 Trading HaltPRICE SENSITIVE20/03/18
BD1 Additional BARD1 Ovarian Test ResultsPRICE SENSITIVE06/03/18
BD1 Half Yearly Report and AccountsPRICE SENSITIVE28/02/18
BD1 Grant of Japanese PatentPRICE SENSITIVE02/02/18
BD1 Quarterly Business Update and Appendix 4CPRICE SENSITIVE30/01/18
BD1 RESULTS OF BARD1 OVARIAN CANCER STUDYPRICE SENSITIVE09/01/18
BD1 Quarterly Business Update and Appendix 4CPRICE SENSITIVE30/10/17
BD1 Research and Development UpdatePRICE SENSITIVE04/10/17
BD1 Appendix 4E Preliminary Financial ResultsPRICE SENSITIVE31/08/17
BD1 Publication of BARD1 Lung Cancer TestPRICE SENSITIVE08/08/17
BD1 Australian Patent IssuedPRICE SENSITIVE07/08/17
BD1 Quarterly Activities Report & Appendix 4CPRICE SENSITIVE27/07/17
BD1 Capital RaisingPRICE SENSITIVE05/07/17
BD1 Trading HaltPRICE SENSITIVE03/07/17
BD1 Shareholder UpdatePRICE SENSITIVE28/06/17
BD1 Lung Cancer Study ResultsPRICE SENSITIVE15/05/17
BD1 Quarterly Activities Report and Appendix 4CPRICE SENSITIVE28/04/17
BD1 Cancer Vaccine CollaborationPRICE SENSITIVE05/04/17
BD1 OVARIAN CANCER CLINICAL STUDY RESULTSPRICE SENSITIVE23/03/17
BD1 GRANT OF U.S. PATENTPRICE SENSITIVE23/03/17
BD1 Appendix 4D and Half Yearly Reports and AccountsPRICE SENSITIVE28/02/17
BD1 Successful Assay Feasibility ResultsPRICE SENSITIVE08/02/17
BD1 Quarterly Activities Review and Appendix 4CPRICE SENSITIVE31/01/17
BD1 Appointment of CEO-BD1.AX PRICE SENSITIVE03/11/16
BD1 Appointment of CEOPRICE SENSITIVE03/11/16
BD1 Quarterly Activities Report and Appendix 4C-BD1.AX PRICE SENSITIVE31/10/16
BD1 Company Update - Promising Result for Ovarian Cancer-BD1.AX PRICE SENSITIVE22/09/16
BD1 Preliminary Final Report - Appendix 4E-BD1.AX PRICE SENSITIVE31/08/16
BD1 Quarterly Activities Report and Appendix 4C-BD1.AX PRICE SENSITIVE28/07/16
BD1 Half Yearly Report and Accounts
28/02/19PRICE SENSITIVE
BD1 Cancer Vaccine Study Results
15/02/19PRICE SENSITIVE
BD1 Quarterly Business Update and Appendix 4C
25/01/19PRICE SENSITIVE
BD1 Closure of Entitlement Offer and Shortfall
12/12/18PRICE SENSITIVE
BD1 Rights Offer Document
19/11/18PRICE SENSITIVE
BD1 Capital Raising Indicative Timetable
12/11/18PRICE SENSITIVE
BD1 Non-Renounceable Issue
08/11/18PRICE SENSITIVE
BD1 Trading Halt
07/11/18PRICE SENSITIVE
BD1 Pause In Trading
07/11/18PRICE SENSITIVE
BD1 Quarterly Activities Report and Cashflow
31/10/18PRICE SENSITIVE
BD1 Grant of Additional Chinese Patent Core BARD1 Patent Family
24/10/18PRICE SENSITIVE
BD1 Development of world first BARD1 Breast Cancer Test
23/10/18PRICE SENSITIVE
BD1 Bard1 Ovarian Test Results
06/09/18PRICE SENSITIVE
BD1 Appendix 4E
31/08/18PRICE SENSITIVE
BD1 Quarterly Activities Report and Appendix 4C
01/08/18PRICE SENSITIVE
BD1 US Patent Issued Protecting BARD1 Ovarian Test
12/07/18PRICE SENSITIVE download Created with Sketch. 141.15KB
BD1 Improved Performance of BARD1 Ovarian Test
19/06/18PRICE SENSITIVE download Created with Sketch. 136.84KB
BD1 Reinstatement to Official Quotation
18/05/18PRICE SENSITIVE
BD1 Response to ASX Price Query
18/05/18PRICE SENSITIVE
BD1 Contract Development Agreement Signed
18/05/18PRICE SENSITIVE
BD1 Voluntary Suspension
14/05/18PRICE SENSITIVE
BD1 Trading Halt
10/05/18PRICE SENSITIVE
BD1 Quarterly Business Update and Appendix 4C
30/04/18PRICE SENSITIVE
BD1 Capital Raising
22/03/18PRICE SENSITIVE
BD1 Israeli Patent Issued in Bard1 Core Patent Family
21/03/18PRICE SENSITIVE
BD1 Trading Halt
20/03/18PRICE SENSITIVE
BD1 Additional BARD1 Ovarian Test Results
06/03/18PRICE SENSITIVE
BD1 Half Yearly Report and Accounts
28/02/18PRICE SENSITIVE
BD1 Grant of Japanese Patent
02/02/18PRICE SENSITIVE
BD1 Quarterly Business Update and Appendix 4C
30/01/18PRICE SENSITIVE
BD1 RESULTS OF BARD1 OVARIAN CANCER STUDY
09/01/18PRICE SENSITIVE
BD1 Quarterly Business Update and Appendix 4C
30/10/17PRICE SENSITIVE
BD1 Research and Development Update
04/10/17PRICE SENSITIVE
BD1 Appendix 4E Preliminary Financial Results
31/08/17PRICE SENSITIVE
BD1 Publication of BARD1 Lung Cancer Test
08/08/17PRICE SENSITIVE
BD1 Australian Patent Issued
07/08/17PRICE SENSITIVE
BD1 Quarterly Activities Report & Appendix 4C
27/07/17PRICE SENSITIVE
BD1 Capital Raising
05/07/17PRICE SENSITIVE
BD1 Trading Halt
03/07/17PRICE SENSITIVE
BD1 Shareholder Update
28/06/17PRICE SENSITIVE
BD1 Lung Cancer Study Results
15/05/17PRICE SENSITIVE
BD1 Quarterly Activities Report and Appendix 4C
28/04/17PRICE SENSITIVE
BD1 Cancer Vaccine Collaboration
05/04/17PRICE SENSITIVE
BD1 OVARIAN CANCER CLINICAL STUDY RESULTS
23/03/17PRICE SENSITIVE
BD1 GRANT OF U.S. PATENT
23/03/17PRICE SENSITIVE
BD1 Appendix 4D and Half Yearly Reports and Accounts
28/02/17PRICE SENSITIVE
BD1 Successful Assay Feasibility Results
08/02/17PRICE SENSITIVE
BD1 Quarterly Activities Review and Appendix 4C
31/01/17PRICE SENSITIVE
BD1 Appointment of CEO-BD1.AX
03/11/16PRICE SENSITIVE
BD1 Appointment of CEO
03/11/16PRICE SENSITIVE
BD1 Quarterly Activities Report and Appendix 4C-BD1.AX
31/10/16PRICE SENSITIVE
BD1 Company Update - Promising Result for Ovarian Cancer-BD1.AX
22/09/16PRICE SENSITIVE
BD1 Preliminary Final Report - Appendix 4E-BD1.AX
31/08/16PRICE SENSITIVE
BD1 Quarterly Activities Report and Appendix 4C-BD1.AX
28/07/16PRICE SENSITIVE
refresh Created with Sketch. REFRESH
 

Top Stories

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

Pan Asia Metals has scored $35 million from a New York private equity firm at the same time as the company's big rebrand push begins.
MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up Who the MinRes Board has decided to move on faster may or may not be amusing, depending on how much you've lost.
Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing Bigtincan Holdings has fielded an offer from Investcorp. But if you think it's underwhelming – consider Wall Street volumes.
To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels Put simply: if 3D Printing is a gold rush, Amaero is selling shovels. Or maybe it's more like sneakers in an arms race.
Alcidion inks deal with Vic health provider Peninsula for use of Miya Precision tech Alcidion Group Ltd has signed a contract worth $3.7M to enable use of its Miya Precision platform by users of Peninsula Health entities
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.